Literature DB >> 1397207

Surveillance and treatment of liver transplant recipients for candidiasis and aspergillosis.

M A Viviani1, A M Tortorano, C Malaspina, M Colledan, G Paone, G Rossi, G Bordone, A Pagano.   

Abstract

Between June 1988 and May 1991 88 orthotopic liver transplants and 1 liver and pancreas transplant were performed at the Liver Transplantation Department of the Ospedale Maggiore of Milan. All the patients underwent mycological surveillance and received antifungal prophylaxis with oral amphotericin B (6000 mg/day) or oral or intravenous fluconazole (200 mg/day) from the time of their transplant. The incidence of Candida colonization was 67%. Fluconazole was superior to oral amphotericin B in the treatment of C. albicans colonization (9/9 vs 6/15), but less effective in the treatment of colonization by other Candida spp. (0/3 vs 3/3). Deep-seated candidiasis developed in 5 patients, caused by C. albicans in 4 cases and C. krusei in 1. C. albicans infection resolved rapidly with fluconazole in 2 subjects, with intravenous amphotericin B alone in 1, and with amphotericin B plus flucytosine in the other. On the contrary, C. krusei infection did not respond to treatment with amphotericin B combined with flucytosine. Aspergillosis was diagnosed in 11 patients, of whom 4 died from invasive aspergillosis, despite 15 and 26 days of amphotericin B treatment in 2. In another patient invasive aspergillosis, diagnosed a few hours before retransplantation, improved with liposomal amphotericin B, but this man died from cytomegalovirus infection one month later. Aspergillosis was eradicated by itraconazole in 4 other patients and by topical amphotericin B in 2 whose infection was localized to surgical wound.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1397207     DOI: 10.1007/bf00158579

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  4 in total

1.  Aspergillus fumigatus infections in liver transplant patients.

Authors:  G Rossi; A M Tortorano; M A Viviani; A Pagano; M Colledan; L R Fassati; G Ferla; B Gridelli; P Reggiani; M Doglia
Journal:  Transplant Proc       Date:  1989-02       Impact factor: 1.066

2.  The incidence and diagnosis of invasive fungal infections in liver transplant recipients.

Authors:  J Tollemar; B G Ericzon; K Holmberg; J Andersson
Journal:  Transplant Proc       Date:  1990-02       Impact factor: 1.066

3.  Fungal infections in liver transplant recipients.

Authors:  C P Wajszczuk; J S Dummer; M Ho; D H Van Thiel; T E Starzl; S Iwatsuki; B Shaw
Journal:  Transplantation       Date:  1985-10       Impact factor: 4.939

4.  Infections after liver transplantation. An analysis of 101 consecutive cases.

Authors:  S Kusne; J S Dummer; N Singh; S Iwatsuki; L Makowka; C Esquivel; A G Tzakis; T E Starzl; M Ho
Journal:  Medicine (Baltimore)       Date:  1988-03       Impact factor: 1.889

  4 in total
  4 in total

Review 1.  Antifungal prophylaxis during neutropenia and immunodeficiency.

Authors:  O Lortholary; B Dupont
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

2.  Guidelines for the investigation of invasive fungal infections in haematological malignancy and solid organ transplantation. British Society for Medical Mycology.

Authors:  D W Denning; E G Evans; C C Kibbler; M D Richardson; M M Roberts; T R Rogers; D W Warnock; R E Warren
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-06       Impact factor: 3.267

3.  Antigenic properties and processing requirements of 65-kilodalton mannoprotein, a major antigen target of anti-Candida human T-cell response, as disclosed by specific human T-cell clones.

Authors:  R Nisini; G Romagnoli; M J Gomez; R La Valle; A Torosantucci; S Mariotti; R Teloni; A Cassone
Journal:  Infect Immun       Date:  2001-06       Impact factor: 3.441

4.  SCH 51048, a new antifungal triazole active against hematogenous Candida krusei infections in neutropenic mice.

Authors:  N C Karyotakis; M C Dignani; E J Anaissie
Journal:  Antimicrob Agents Chemother       Date:  1995-03       Impact factor: 5.191

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.